Three recent studies showed that paricalcitol reduces proteinuria in patients with CKD, including those presenting with diabetes.184–186 Paricalcitol reduced albuminuria and slowed the progression of kidney injury in laboratory animals.187,188 A recent double-blind, placebo-controlled study resulted in a 20% reduction in the urinary albumin-to-creatinine ratios (P=0.053) and a 28% reduction in the 24-hour urine albumin (P=0.009) of patients receiving 2 μg of paricalcitol for 24 weeks compared with those receiving a placebo.189. This evidence concerns the gene ALB and chronic kidney disease.